BIODESIX INC — Form 10-Q
Filed August 5, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 45/100
What the filing says
Biodesix entered into a Supply Agreement effective April 1, 2026 with Freenome Limited to manufacture and supply coated plates and reagents for blood-based autoantibody testing (Initial Product). The agreement replaces prior 2019 and 2025 interim agreements. Key financial terms are redacted [***], but the agreement establishes Freenome as sole manufacturer at its Nottingham facility, with Biodesix having audit rights, quality standards per ISO 13485, and provisions for product rejection, defect remediation, and supply failure management.
Why this rating
Supply agreement is routine operational contract for $19.6M company; establishes manufacturing continuity but lacks disclosed pricing/volume specifics. Moderate significance due to supply chain dependency, not transformational.
See more from August 5, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.